Stability and perfusion studies of desmopressin (dDAVP) and prodrugs in the rat jejunum

Experimental and Toxicologic Pathology

Volumn 51, Issue 4-5, 1999, Pages 363-368

  Lepist, Eve Irene ^a,c   Østergaard, Jesper ^a   Fredholt, Karin ^a   Lennernäs, Hans ^b   Friis, Gitte Juel ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF TARTU   (Estonia)

Author keywords

DDAVP; Desmopressin; Prodrugs; Rat perfusion; Stability; Vasopressin analogue

Indexed keywords

DESMOPRESSIN; ESTERASE; PRODRUG;

ANIMAL TISSUE; CONFERENCE PAPER; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG STABILITY; ENZYME ACTIVITY; INTESTINE ABSORPTION; INTESTINE FLUID; NOCTURNAL ENURESIS; NONHUMAN; QUANTITATIVE DIAGNOSIS; RAT; STEREOCHEMISTRY;

ANIMALIA;

EID: 0032765844     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0940-2993(99)80023-2     Document Type: Conference Paper

References (17)

1. ALDRIDGE WN: Serum esterases (1). Two types of esterases (A and B) hydrolysing p-nitrophenylacetate, proprionate and buryrate, and a method of their determination. Biochemical Journal 1953; 53: 110-117.
2. AUGUSTIJNS P, ANNAERT P, HEYLEN P, et al.: Drug absorption of prodrug esters using the Caco-2 model: evaluation of ester hydrolysis and transepithelial transport. Int J Pharm Sci 1998; 166: 45-53.
3. BUNDGAARD H: Means to enhance penetration. Prodrugs as a means to improve the delivery of peptide drugs. Adv Drug Del Rev 1992; 8: 1-38.
4. FAGERHOLM U, JOHANSSON M, LENNERNÄS H: Comparison between permeability coefficients in rat and human jejunum. Pharm Res 1996; 13: 1336-1342.
5. FJELLESTAD-PAULSEN A, HÖGLUND P, LUNDIN S, et al.: Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol 1993; 38: 177-182.
6. GANGWAR S, PAULETTI GM, WANG B, et al.: Prodrug strategies to enhance the intestinal absorption of peptides. Drug Disc Today 1997; 2: 148-155.
7. KAHNS AH, BUUR A, BUNDGAARD H: Prodrugs of peptides. 18. Synthesis and evaluation of various esters of Desmopressin (dDAVP). Pharm Res 1993; 10: 68-74.
8. KIHLBERG J, AHMAN J, WALSE B, et al.: Glycosylated peptide hormones: Pharmacological properties and conformational studies of analogues of [1-Desamino, 8-D-arginine]-vasopressin. J Med Chem 1995; 38: 161-169.
9. KRONDAHL E, ORZECHOVSKI A, EKSTROM G, et al.: Rat jejunal permeability and metabolism of μ-selective tetrapeptides in gastrointestinal fluids from humans and rats. Pharm Res 1997; 12: 1780-1785.
10. LUNDIN PDP, BOJRUP M, LJUSBERG-WAHREN H, et al.: Enhancing effects of monohexanoin and two other medium-chain glyceride vehicles on intestinal absorption of Desmopressin (dDAVP). J Pharmacol Exp Thera 1997; 282: 585-590.
11. LUNDIN S, ARTHURSSON P: Absorption of a vasopressin analogue, 1-deamino-8-D-arginine (dDAVP) in a human intestinal epithelial cell line, Caco-2. Int J Pharm 1990; 64: 181-186.
12. 8]-vasopressin (dDAVP) in pancreatic juice and intestinal mucosa homogenate. Pharmacol Toxicol 1989; 65: 92-95.
13. NIELSEN NM, BUNDGAARD H: Prodrugs as drug delivery systems.68. Chemical and plasma catalyzed hydrolysis of various esters of benzoic acid: a reference system for designing prodrug esters of carboxylic acid agents. Int J Pharm Sci 1987; 39: 75-85.
14. OLIYAI R: Prodrugs of peptides and peptidomimetics for improved formulation and delivery. Adv Drug Del Rev 1996; 19: 275-286.
15. OLIYAI R, STELLA VJ: Prodrugs of peptides and proteins for improved formulation and delivery. Ann Rev Pharmacol Toxicol 1993; 32: 521-544.
16. VILHARDT H: Basic pharmacology of Desmopressin. A review. Drug Invest 1990; 2: 2-8.
17. VILHARDT H, LUNDIN S: Biological effect and plasma concentrations of dDAVP after intranasal and peroral administration to humans. Gen Pharmacol 1986; 17: 481-483.